

**MD MEDICAL GROUP POSTS STRONG GROWTH ACROSS ALL
OPERATIONAL INDICATORS FOR 9M 2016**

24 October 2016, Moscow – MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE: MDMG), a leading Russian private healthcare provider, today announces its operating results for the third quarter and nine months of 2016.

Key operational highlights for 9M 2016:

- Total deliveries increased 22% year-on-year (y-o-y) to 5,018
- Total IVF cycles increased 52% y-o-y to 10,011
- Total in-patient treatments increased 11% y-o-y to 41,582
- Total out-patient treatments increased 18% y-o-y to 1,018,117

Mark Kurtser, CEO of MD Medical Group, said:

“Nine months is an important period, especially in our business. And we are glad to announce that thanks to continued strong growth across all operational parameters in Q3 we have successfully completed the first nine months of 2016.”

“During the period we had 22% more deliveries than in 9M 2015. The number of IVF cycles grew by more than 1.5x and has already exceeded the results of FY 2015. No other company in Russia ever completed more than 10,000 IVF cycles within a nine-month period. In-patient and out-patient treatments grew 11% and 18% year-on-year, respectively.”

“Key drivers of this growth included continued ramp-up at our Lapino, Ufa and PMC hospitals. The remarkable growth in the IVF segment was largely driven by our new clinics in Siberia, which delivered approximately 2,000 cycles, as well as other clinics.”

“We are satisfied with our dynamics this year to date and are committed to maintaining the positive trend going forward in 2016.”

Deliveries

- In 9M 2016, total deliveries increased 22% y-o-y to 5,018.
- In Q3 2016, total deliveries increased 24% y-o-y to 1,815.
- In 9M 2016, there were 786 deliveries at Mother & Child Ufa hospital.

IVF

- In 9M 2016, total IVF cycles rose 52% y-o-y to 10,011.
- In Q3 2016, total IVF cycles rose 44% y-o-y to 3,443.
- In 9M 2016, LFL¹ 8,069 IVF cycles were performed, up 22% y-o-y.

In-patient treatments

- In 9M 2016, total in-patient treatments grew 11% y-o-y to 41,582, driven by:
 - 4% increase in OBGYN in-patient treatments;
 - 21% increase in paediatric in-patient treatments;
 - 12% increase in in-patient days using other medical services.
- In Q3 2016, the total number of in-patient days increased 16% y-o-y to 13,432.
- In 9M 2016, LFL in-patient treatments increased 11% y-o-y to 41,540.

Out-patient treatments

- In 9M 2016, the total number of out-patient treatments increased 18% y-o-y to 1,018,117, driven by:
 - 12% increase in OBGYN out-patient treatments;
 - 15% rise in paediatric out-patient visits;
 - 28% increase in other medical services.
- In Q3 2016, the total number of out-patient treatments increased 16% y-o-y to 338,499.
- In 9M 2016, LFL out-patient treatments increased 11% y-o-y to 954,642.

¹ LFL data does not include figures for the Medica clinic (Novokuznetsk) and ARTMedGroup clinics (Krasnoyarsk, Omsk, Barnaul, and Novosibirsk), which have been consolidated since January 2016, as well as figures for the Kostroma clinic, which opened in April 2016.

TOTAL							LFL		
	9M 2016	9M 2015	y-o-y, %	3Q 2016	3Q 2015	y-o-y, %	9M 2016	9M 2015	y-o-y, %
Obstetrics and Gynaecology									
Deliveries	5,018	4,113	22%	1,815	1,462	24%	5,018	4,113	22%
In-patient treatments (except deliveries)	18,027	17,397	4%	6,057	5,687	7%	18,027	17,397	4%
Out-patient treatments	374,619	334,204	12%	127,690	113,907	12%	358,428	334,204	7%
IVF									
	10,011	6,603	52%	3,443	2,392	44%	8,069	6,603	22%
Paediatrics									
In-patient treatments	13,706	11,373	21%	4,313	3,114	39%	13,706	11,373	21%
Out-patient treatments	287,841	251,030	15%	95,181	82,887	15%	287,663	251,030	15%
Other medical services									
In-patient treatments	9,849	8,780	12%	3,062	2,800	9%	9,807	8,780	12%
Out-patient treatments	355,657	277,591	28%	115,628	90,261	28%	308,551	277,591	11%
Total									
Total deliveries	5,018	4,113	22%	1,815	1,462	24%	5,018	4,113	22%
Total IVF	10,011	6,603	52%	3,443	2,392	44%	8,069	6,603	22%
Total in-patient treatments	41,582	37,550	11%	13,432	11,601	16%	41,540	37,550	11%
Total out-patient treatments	1,018,117	862,825	18%	338,499	287,055	18%	954,642	862,825	11%

For further information please contact:

Investors

Elena Romanova
MD Medical Group Investments Plc
Tel: +7 495 331 4120
e.romanova@mcclinics.ru

Media

EM
Tom Blackwell: +7 919 102 9064
Sergii Pershyn: +1 929 855 8188
MDMG@em-comms.com

About MD Medical Group

MD Medical Group operates in the highly attractive Russian private healthcare service market and has a leading position in high-quality women's health and paediatrics. The company manages 31 modern healthcare facilities, including 4 hospitals and 27 outpatient clinics in Moscow and Moscow region, St. Petersburg, Ufa, Perm, Samara and Samara region, Irkutsk, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, and Barnaul.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Forward-Looking Statements:

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.